Top Chinese drugmaker Hengrui soars in Hong Kong trading debut


Hengrui’s debut, which comes on the heels of CATL’s blockbuster Hong Kong premiere, builds on Hong Kong’s hot listings market—where proceeds are forecast to double to more than $22 billion this year.

Hengrui’s debut, which comes on the heels of CATL’s blockbuster Hong Kong premiere, builds on Hong Kong’s hot listings market—where proceeds are forecast to double to more than $22 billion this year.

May James—SOPA Images/LightRocket via Getty Images


Leave a Reply

Your email address will not be published. Required fields are marked *